Nature medicine, 2011-11, Vol.17 (11), p.1481-1489
- Ellingsgaard, Helga
- Hauselmann, Irina
- Schuler, Beat
- Habib, Abdella M
- Baggio, Laurie L
- Meier, Daniel T
- Eppler, Elisabeth
- Bouzakri, Karim
- Wueest, Stephan
- Muller, Yannick D
- Hansen, Ann Maria Kruse
- Reinecke, Manfred
- Konrad, Daniel
- Gassmann, Max
- Reimann, Frank
- Halban, Philippe A
- Gromada, Jesper
- Drucker, Daniel J
- Gribble, Fiona M
- Ehses, Jan A
- Donath, Marc Y
2011
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Ellingsgaard, Helga
- Hauselmann, Irina
- Schuler, Beat
- Habib, Abdella M
- Baggio, Laurie L
- Meier, Daniel T
- Eppler, Elisabeth
- Bouzakri, Karim
- Wueest, Stephan
- Muller, Yannick D
- Hansen, Ann Maria Kruse
- Reinecke, Manfred
- Konrad, Daniel
- Gassmann, Max
- Reimann, Frank
- Halban, Philippe A
- Gromada, Jesper
- Drucker, Daniel J
- Gribble, Fiona M
- Ehses, Jan A
- Donath, Marc Y
- Titel
- Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
- Ist Teil von
- Nature medicine, 2011-11, Vol.17 (11), p.1481-1489
- Ort / Verlag
- United States: Nature Publishing Group
- Erscheinungsjahr
- 2011
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Exercise, obesity and type 2 diabetes are associated with elevated plasma concentrations of interleukin-6 (IL-6). Glucagon-like peptide-1 (GLP-1) is a hormone that induces insulin secretion. Here we show that administration of IL-6 or elevated IL-6 concentrations in response to exercise stimulate GLP-1 secretion from intestinal L cells and pancreatic alpha cells, improving insulin secretion and glycemia. IL-6 increased GLP-1 production from alpha cells through increased proglucagon (which is encoded by GCG) and prohormone convertase 1/3 expression. In models of type 2 diabetes, the beneficial effects of IL-6 were maintained, and IL-6 neutralization resulted in further elevation of glycemia and reduced pancreatic GLP-1. Hence, IL-6 mediates crosstalk between insulin-sensitive tissues, intestinal L cells and pancreatic islets to adapt to changes in insulin demand. This previously unidentified endocrine loop implicates IL-6 in the regulation of insulin secretion and suggests that drugs modulating this loop may be useful in type 2 diabetes.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1078-8956eISSN: 1546-170XDOI: 10.1038/nm.2513Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4286294
- Format
- –
- Schlagworte
- Animals, Blood Glucose - metabolism, Care and treatment, Cells, Cultured, Cellular biology, Diabetes, Diabetes Mellitus, Type 2 - metabolism, Diabetes Mellitus, Type 2 - physiopathology, Diet, High-Fat, Disease Models, Animal, Endocrinology, Enteroendocrine Cells - drug effects, Enteroendocrine Cells - metabolism, Female, Genetic aspects, Glucagon-Like Peptide 1 - metabolism, Glucagon-Secreting Cells - drug effects, Glucagon-Secreting Cells - metabolism, Glucose Tolerance Test, Humans, Insulin, Insulin - metabolism, Insulin Secretion, Interleukin-6, Interleukin-6 - antagonists & inhibitors, Interleukin-6 - genetics, Interleukin-6 - metabolism, Interleukin-6 - pharmacology, Male, Mice, Mice, Inbred C57BL, Mice, Transgenic, Pancreas, Peptides, Pharmacology, Physical Conditioning, Animal, Physiological aspects, Signal Transduction - drug effects, Signal Transduction - physiology, Type 2 diabetes